Sections
| Title | Starting Page | Number of Pages |
|---|
| Table of Contents | 3 | 5 |
| List of Tables | 5 | 1 |
| List of Figures | 6 | 2 |
| Emerging Pharmaceutical Market - Czech Republic - Introduction | 8 | 1 |
| GBI Research Report Guidance | 8 | 1 |
| Emerging Pharmaceutical Market - Czech Republic - Industry Characterstics | 9 | 16 |
| Market Size and Market Forecast | 9 | 1 |
| Market Share by Indication | 10 | 1 |
| Branded versus Generic Share | 11 | 1 |
| R&D Expenditure Innovations | 11 | 3 |
| Top Pharmaceutical Companies | 14 | 1 |
| Zentiva (Sanofi) | 14 | 1 |
| PLIVA-Lachema (Teva) | 14 | 1 |
| Teva Czech Industries s.r.o | 14 | 1 |
| Lonza Biotec (Lonza) | 14 | 1 |
| FARMAK | 15 | 1 |
| Walmark | 15 | 1 |
| Pfizer | 15 | 1 |
| Novartis | 15 | 1 |
| Merck | 16 | 1 |
| AstraZeneca | 16 | 1 |
| GlaxoSmithKline | 16 | 1 |
| Foreign Direct Investment | 17 | 1 |
| Marketing Distribution Channel | 18 | 2 |
| Exports and Imports | 20 | 1 |
| Exports | 20 | 1 |
| Imports | 21 | 1 |
| Market Drivers and Restraints | 22 | 1 |
| Drivers | 22 | 1 |
| Established Generic Industry | 22 | 1 |
| High Quality Infrastructure | 22 | 1 |
| Increasing Ageing Population | 23 | 1 |
| Rising Pharmaceutical Product Exports | 23 | 1 |
| Restraints | 23 | 1 |
| Government Reforms Plans To Reign Drug Expenses | 23 | 1 |
| Specific Pricing and Reimbursement Levels | 24 | 1 |
| Industry Analysis | 24 | 1 |
| Emerging Pharmaceutical Market - Czech Republic - Macroeconomic Environment | 25 | 22 |
| Demographic Analysis | 25 | 1 |
| Population Size, Growth, and Structure | 25 | 3 |
| Life Expectancy at Birth | 28 | 2 |
| Disease Overview in Czech Republic | 30 | 1 |
| Number of Deaths Occurring by Major Diseases in Czech Republic | 30 | 1 |
| Cardiovascular Diseases (CVD) | 31 | 1 |
| Cancer | 32 | 1 |
| Respiratory Diseases | 33 | 1 |
| Diabetes | 34 | 1 |
| GDP | 35 | 4 |
| Per Capita Income | 39 | 1 |
| Healthcare Expenditure | 40 | 1 |
| Context | 40 | 2 |
| Analytical Framework | 42 | 1 |
| Healthcare Infrastructure | 43 | 1 |
| Context | 43 | 1 |
| Analytical Framework | 44 | 1 |
| Number of Active Healthcare Professionals | 45 | 1 |
| Number of Beds | 45 | 2 |
| Emerging Pharmaceutical Market - Czech Republic - Healthcare Regulation | 47 | 9 |
| Pharmaceutical Regulation in Czech Republic | 47 | 1 |
| Healthcare System Structure | 47 | 1 |
| Recent Healthcare Reform Plans | 47 | 1 |
| Intellectual property Rights (IPR) and entry of Generics | 48 | 1 |
| Health Insurance Coverage | 49 | 1 |
| Public Insurance Coverage | 50 | 1 |
| Private Insurance Coverage | 50 | 1 |
| Pricing and Reimbursement | 50 | 1 |
| Pricing | 51 | 1 |
| Reimbursement | 51 | 1 |
| New Drug Approval Process | 52 | 1 |
| Clinical Trials | 53 | 1 |
| Context | 53 | 1 |
| Analytical Framework | 53 | 2 |
| Regulatory Bodies | 55 | 1 |
| State Institute for Drug Control | 55 | 1 |
| Czech Ministry of Health | 55 | 1 |
| Emerging Pharmaceutical Market - Czech Republic - Industry Trends | 56 | 6 |
| Mergers and Acquisitions | 56 | 1 |
| Deals by Year | 56 | 1 |
| Deals by Type | 57 | 1 |
| Deal by Value | 58 | 1 |
| Top M&A Deals | 59 | 1 |
| Sanofi-Aventis Acquires Majority Stake in Zentiva | 59 | 1 |
| Zentiva Acquires Remaining 25% Stake In Eczacibasi-Zentiva | 59 | 1 |
| Recordati Acquires HERBACOS-BOFARMA | 59 | 1 |
| Cryo-Save Group Acquires Sejtbank Egeszsegugyi Szolgaltato Korlatolt Felelossegu Tarsasag And Cryo-Save | 60 | 1 |
| Licensing Agreements | 60 | 1 |
| Deals by Year | 60 | 1 |
| Top Three Licensing Deals | 61 | 1 |
| Sinclair IS Pharma Enters Into Licensing Agreement With Teva Pharmaceuticals For Episil | 61 | 1 |
| AbCheck Enters Into Licensing Agreement With Celexion | 61 | 1 |
| Kadmon Pharmaceuticals Enters Into Licensing Agreement with Valeant Pharmaceuticals for Ribavirin | 61 | 1 |
| Emerging Pharmaceutical Market - Czech Republic - CRO Industry | 62 | 15 |
| Clinical Research Organization (CRO) | 62 | 1 |
| CRO Company Profiles - Foreign Players | 62 | 1 |
| Quintiles | 62 | 1 |
| Business Description | 63 | 1 |
| PPD | 64 | 1 |
| Business Description | 64 | 1 |
| Covance | 65 | 1 |
| Business Description | 65 | 1 |
| Inc Research | 66 | 1 |
| Business Description | 66 | 1 |
| PAREXEL | 67 | 1 |
| Business Description | 67 | 1 |
| Chiltern | 68 | 1 |
| Business Description | 68 | 1 |
| MEDPACE | 69 | 1 |
| Business Description | 69 | 1 |
| PRA International | 70 | 1 |
| Business Description | 70 | 1 |
| CRO Company Profiles - Domestic Players | 71 | 1 |
| CEPHA | 71 | 1 |
| Business Description | 71 | 1 |
| KCR | 72 | 1 |
| Business Description | 72 | 1 |
| A-Pharma | 73 | 1 |
| Business Description | 73 | 1 |
| EastHORN | 74 | 1 |
| Business Description | 74 | 1 |
| Prague Clinical Services | 75 | 1 |
| Business Description | 75 | 1 |
| PHARMNET | 76 | 1 |
| Business Description | 76 | 1 |
| Emerging Pharmaceutical Market - Czech Republic - Appendix | 77 | 3 |
| Market Definitions | 77 | 1 |
| Abbreviations | 77 | 1 |
| Research Methodology | 77 | 2 |
| Industry Performance | 78 | 1 |
| Macroeconomic Environment | 78 | 1 |
| Healthcare Regulations | 78 | 1 |
| Industry Trends | 78 | 1 |
| Contact Us | 78 | 1 |
| Disclaimer | 78 | 1 |
| Sources | 79 | 1 |